David Altshuler Vertex Pharmaceuticals Inc (VRTX) insider trading activity

David Altshuler is EVP, Chief Scientific Officer of VERTEX PHARMACEUTICALS INC . Currently has a direct ownership of 25,813 shares of VRTX, which is worth approximately $13 Million. The most recent transaction as insider was on May 15, 2024, when has been sold 54 shares (Common Stock) at a price of $430.93 per share, resulting in proceeds of $23,270. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 25.8K

0% 3M change

19.43% 12M change

Total Value Held $13 Million

DAVID ALTSHULER Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 15 2024	SELL Open market or private sale	$23,270 $430.93 p/Share	54 Reduced 0.21%	25,813 Common Stock
Feb 26 2024	SELL Open market or private sale	$1,804,542 $425.7 p/Share	4,239 Reduced 14.11%	25,813 Common Stock
Feb 23 2024	SELL Payment of exercise price or tax liability	$1,714,206 $431.79 p/Share	3,970 Reduced 11.67%	30,052 Common Stock
Feb 21 2024	SELL Open market or private sale	$1,266,153 $421.77 p/Share	3,002 Reduced 8.11%	34,022 Common Stock
Feb 20 2024	SELL Open market or private sale	$1,684,001 $420.79 p/Share	4,002 Reduced 9.75%	37,024 Common Stock
Feb 20 2024	SELL Payment of exercise price or tax liability	$1,182,670 $420.58 p/Share	2,812 Reduced 6.41%	41,026 Common Stock
Feb 16 2024	SELL Payment of exercise price or tax liability	$1,590,037 $424.01 p/Share	3,750 Reduced 7.88%	43,838 Common Stock
Feb 12 2024	SELL Open market or private sale	$1,321,654 $420.24 p/Share	3,145 Reduced 6.2%	47,588 Common Stock
Feb 09 2024	SELL Payment of exercise price or tax liability	$887,331 $422.74 p/Share	2,099 Reduced 3.97%	50,733 Common Stock
Feb 07 2024	BUY Grant, award, or other acquisition	-	7,114 Added 11.87%	52,832 Common Stock
Feb 06 2024	BUY Grant, award, or other acquisition	-	13,680 Added 23.03%	45,718 Common Stock
Nov 15 2023	SELL Open market or private sale	$7,028 $369.92 p/Share	19 Reduced 0.06%	32,038 Common Stock
Aug 09 2023	SELL Open market or private sale	$21,767 $345.51 p/Share	63 Reduced 0.2%	32,038 Common Stock
Feb 27 2023	SELL Open market or private sale	$1,222,747 $288.52 p/Share	4,238 Reduced 11.68%	32,038 Common Stock
Feb 24 2023	SELL Payment of exercise price or tax liability	$1,147,806 $289.12 p/Share	3,970 Reduced 9.86%	36,276 Common Stock
Feb 21 2023	SELL Open market or private sale	$1,173,106 $293.13 p/Share	4,002 Reduced 9.04%	40,246 Common Stock
Feb 17 2023	SELL Payment of exercise price or tax liability	$1,098,187 $292.85 p/Share	3,750 Reduced 7.81%	44,248 Common Stock
Feb 14 2023	SELL Open market or private sale	$1,909,611 $298.47 p/Share	6,398 Reduced 11.76%	47,998 Common Stock
Feb 13 2023	SELL Open market or private sale	$1,432,826 $298.63 p/Share	4,798 Reduced 8.11%	54,396 Common Stock
Feb 13 2023	SELL Payment of exercise price or tax liability	$1,786,577 $298.26 p/Share	5,990 Reduced 9.19%	59,194 Common Stock
Feb 10 2023	SELL Payment of exercise price or tax liability	$1,018,676 $294.33 p/Share	3,461 Reduced 5.04%	65,184 Common Stock
Feb 06 2023	SELL Open market or private sale	$397,041 $304.48 p/Share	1,304 Reduced 1.86%	68,645 Common Stock
Feb 06 2023	BUY Exercise of conversion of derivative security	$244,539 $187.53 p/Share	1,304 Added 1.83%	69,949 Common Stock
Feb 01 2023	BUY Grant, award, or other acquisition	-	32,568 Added 32.18%	68,645 Common Stock
Nov 15 2022	SELL Open market or private sale	$10,492 $308.61 p/Share	34 Reduced 0.09%	36,077 Common Stock

David Altshuler

EVP, Chief Scientific Officer

Boston, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells VRTX shares.

Notify only if

Value

Insider Trading

Get notified when an Vertex Pharmaceuticals Inc insider buys or sells VRTX shares.

Notify only if

Operation

Value

Type

News

Receive news related to VERTEX PHARMACEUTICALS INC

Track Activities on VRTX

Account